Novartis announced Thursday that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) were published in the... read more
Novartis announced Thursday that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) were published in the... read more
The House passed the so called “Right to Try” bill on Wednesday evening. The vote was roughly along party lines, 267-149 with 35 Democrats supporting the bill and 2 Republicans opposed.
... read more
AOBiome Therapeutics today announced clinical findings from Part 1 of a Phase 1b/2a clinical trial of the Company's first-in-class Ammonia Oxidizing Bacteria (AOB) product candidate for... read more
Sun Pharma announced today that the U.S. Food and Drug Administration (FDA) has approved ILUMYA™ (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are... read more
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,